Movatterモバイル変換

[0]ホーム

Jump to content

PD-102,807

Edit links

From Wikipedia, the free encyclopedia

Chemical compound

Pharmaceutical compound

PD-102,807
Identifiers

IUPAC name ethyl 3,6a,11,14-tetrahydro-9-methoxy-2-methyl-(12H)-isoquino[1,2-b]pyrrolo[3,2-f][1,3]benzoxazine-1-carboxylate
CAS Number	23062-91-1^N
PubChemCID	4995951
ChemSpider	4175916^Y
UNII	A7U96364HK
ChEMBL	ChEMBL59898^Y
CompTox Dashboard(EPA)	DTXSID20407355
Chemical and physical data
Formula	C₂₃H₂₄N₂O₄
Molar mass	392.455 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCOC(=O)c1c(C)[nH]c(c1c3C5)ccc3OC2N5CCc4c2ccc(OC)c4
InChI InChI=1S/C23H24N2O4/c1-4-28-23(26)20-13(2)24-18-7-8-19-17(21(18)20)12-25-10-9-14-11-15(27-3)5-6-16(14)22(25)29-19/h5-8,11,22,24H,4,9-10,12H2,1-3H3^Y Key:VDDUJINYXKGZLV-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)

PD-102,807 is a drug which acts as a selectiveantagonist for themuscarinic acetylcholine receptor M₄.^[1]^[2]^[3] It is used in scientific research for studying the effects of the different muscarinic receptor subtypes in the body and brain.^[4]^[5]^[6]^[7]

References

[edit]

^Olianas MC, Onali P (1999). "PD 102807, a novel muscarinic M4 receptor antagonist, discriminates between striatal and cortical muscarinic receptors coupled to cyclic AMP".Life Sciences.65 (21):2233–40.doi:10.1016/S0024-3205(99)00488-9.PMID 10576595.
^Varoli L, Andreani A, Burnelli S, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Bedini A, Fazio N, Spampinato S (May 2008). "Diphenidol-related diamines as novel muscarinic M4 receptor antagonists".Bioorganic & Medicinal Chemistry Letters.18 (9):2972–6.doi:10.1016/j.bmcl.2008.03.061.PMID 18395442.
^Böhme TM, Augelli-Szafran CE, Hallak H, Pugsley T, Serpa K, Schwarz RD (July 2002). "Synthesis and pharmacology of benzoxazines as highly selective antagonists at M(4) muscarinic receptors".Journal of Medicinal Chemistry.45 (14):3094–102.doi:10.1021/jm011116o.PMID 12086495.
^Pujol Lereis VA, Hita FJ, Gobbi MD, Verdi MG, Rodriguez MC, Rothlin RP (March 2006)."Pharmacological characterization of muscarinic receptor subtypes mediating vasoconstriction of human umbilical vein".British Journal of Pharmacology.147 (5):516–23.doi:10.1038/sj.bjp.0706654.PMC 1616972.PMID 16444291.
^Hogan K, Markos F (February 2007). "Muscarinic type 1 receptors mediate part of nitric oxide's vagal facilitatory effect in the isolated innervated rat right atrium".Nitric Oxide: Biology and Chemistry.16 (1):110–7.doi:10.1016/j.niox.2006.05.005.PMID 16843016.
^Myslivecek J, Klein M, Novakova M, Ricny J (July 2008). "The detection of the non-M2 muscarinic receptor subtype in the rat heart atria and ventricles".Naunyn-Schmiedeberg's Archives of Pharmacology.378 (1):103–16.doi:10.1007/s00210-008-0285-8.PMID 18443764.
^Lau BK, Vaughan CW (November 2008). "Muscarinic modulation of synaptic transmission via endocannabinoid signalling in the rat midbrain periaqueductal gray".Molecular Pharmacology.74 (5):1392–8.doi:10.1124/mol.108.045872.PMID 18678620.